ISRCTN23944748已完成不适用
The Role of Thalidomide in Reversing Cachexia in Patients with Oesophageal Cancer
Derby Hospitals NHS Foundation Trust (UK)0 个研究点目标入组 34 人开始时间: 2006年6月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Adults with non-obstructing and inoperable oesophageal cancer (dysphagia score <3, able to swallow a semi-solid diet)
排除标准
- •1. Pre-menopausal women
- •2. Patients receiving any adjuvant chemotherapy or radiotherapy
- •3. Patients with oesophageal obstruction
- •4. Those with established neuropathy
- •5. Patients requiring frequent laser ablation sessions
- •6. Those unable to maintain an adequate caloric intake
- •7. Increased debility
研究者
相似试验
已完成
不适用
The role of Thalidomide in Reversing Cachexia in Patients with Oesophageal CancerCancerISRCTN45162540Record Provided by the NHSTCT Register - 2006 Update - Department of Health12
进行中（未招募）
1 期
The use of Thalidomide as a treatment for the cachexia of incurable upper gastrointestinal adenocarcinomas:a randomised, double-blinded, placebo controlled trial. - Thalidomide in cancer cachexiaEUCTR2005-000371-18-GBPortsmouth Hospitals Trust180
招募中
3 期
Thalidomide in COVID19COVID19.disease diagnosis of COVID-19 confirmed by laboratory testing.U07.1IRCT20170207032444N3Esfahan University of Medical Sciences60
进行中（未招募）
1 期
Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasiaSevere recurrent epistaxis in hereditary hemorrhagic telangiectasiaMedDRA version: 14.1Level: LLTClassification code 10038554Term: Rendu-Osler-Weber syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004096-36-ITOSPEDALE POLICLINICO S. MATTEO31
尚未招募
4 期
Study the effects of combination of Thalidomide and Hydroxyurea in patients diagnosed with ThalassemiaCTRI/2024/07/071470Indian Council of Medical research [ICMR], New Delhi